The addition of CDKis to first-line endocrine therapy has significantly improved objective response rates and progression-free survival (PFS) in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer [1,2,3]. The gene discussed is NR4A1; the disease is breast carcinoma.